NMPA CDE Issues MRCT Benefit-Risk Assessment Guideline

China’s Center for Drug Evaluation (CDE) issued the “Guiding Principles for Benefit-Risk Assessment Based on Multi-regional Clinical Trial Data in the Global Simultaneous R&D of New Drugs (Trial)” on February 11, 2026, and released it on February 24, 2026, as “Announcement No. 18 of 2026.” The guideline took effect on the date of promulgation.

Grounded in “ICH E17: General Principles for Multi-regional Clinical Trial Planning and Design,” the document defines how the CDE will assess benefit-risk in China when multi-regional clinical trial (MRCT) data are used to support marketing applications in China. It builds the existing framework while clarifying operational expectations.

The guidance supports global simultaneous development and review but makes clear that approval depends on rigorous analysis of regional data and clearly demonstrated clinical relevance to Chinese patients.

China Relevance Must Be Built into MRCT Design

The guideline states that regional differences should be considered in advance and throughout development where they may affect efficacy, safety, or overall treatment effect.

It identifies a broad set of intrinsic and extrinsic factors that may differ across regions, including:

• Disease etiology and pathophysiology
• Pharmacokinetic (ADME)
• Demographic and disease characteristics
• Medical practice
• Cultural environment
• Language

This makes regional analysis a design issue, not a late-stage statistical exercise. Sponsors are expected to identify potential sources of heterogeneity early, reflect them in trial planning, and continue evaluating them throughout development.

Use Early Clinical Data to Inform MRCT Design

The guideline places particular weight on early clinical studies, including pharmacokinetic and pharmacodynamic trials, in global simultaneous development.

According to the document, these studies help generate safety/tolerability, PK, PD, and dose-exposure-response data that can inform confirmatory MRCT design, including population selection, dose selection, dosing regimen, and overall development strategy. They also help identify whether regional differences may alter treatment effects.

The guideline does not mandate China-specific data prior to confirmatory MRCTs. It does, however, make clear that where such data are unavailable, sponsors should carefully assess whether differences in body weight, enzyme polymorphisms, or pharmacodynamic effects could alter exposure or exposure-response relationships in Chinese patients.

That shifts more of the burden to later justification. Sponsors may still proceed without prior China data, but they should be prepared to explain how these risks were evaluated and how the confirmatory strategy addressed them.

Prespecify Pooling Strategy Based on Regional Similarity

The document gives explicit attention to pooling strategy. Where sponsors intend to pool regions or subpopulations, the approach should be justified based on intrinsic and extrinsic factors, disease distribution, and similarities across regions.

The strategy should be defined in study documents in advance and supported by ongoing evidence collection during development.

Ensure Regional Representation Supports Interpretation

Justify Regional Sample Size Allocation

Regional sample-size allocation should be scientifically justified and provide sufficient information to support regional evaluation and consistency assessment.

Consistent with ICH E17, there is no single accepted or optimal method. Sponsors may balance approaches, such as:

• Proportional allocation based on region size and disease prevalence Equal allocation across regions

The objective is to preserve feasibility while supporting meaningful region interpretation.

Ensure Balanced Regional Contribution to Study Results

The CDE cautions against scenarios where one region dominates the overall study result.

A globally positive trial may have limited relevance for China if the Chinese or China-relevant sample is too small to support meaningful regional evaluation, or if conclusions are largely driven by non-China regions.

Plan and Implement Cross-Regional Consistency Analysis

The guideline treats cross-regional consistency as a central question in benefit-risk assessment.

Consistency is defined as the absence of clinically meaningful differences in treatment effects across regions. Methods for assessing consistency should be prespecified and may include:

• Descriptive analyses
• Covariate-adjusted analyses
• Region-by-treatment interaction testing

Consistency should be built into the statistical framework prospectively rather than addressed only after divergent results appear.

Apply a Structured Framework to Benefit Assessment

Benefit assessment should go beyond the primary efficacy outcome and consider:

• The relationship between study endpoints and clinical outcomes
• Consistency of benefit across regions
• Consistency across trials and endpoints
• The potential for efficacy extrapolation
• Convenience of use

Assess Benefit Across Four Core Dimensions

• Overall efficacy benefit
• Cross-regional consistency of efficacy
• Regional efficacy estimates
• Subgroup analyses of particular relevance

Subgroup analyses should reflect intrinsic and extrinsic factors that may influence treatment effect, recognising that subgroup definitions may vary across regions.

Apply Parallel Structure to Risk Assessment

Evaluate Safety at Both Global and Regional Levels

Risk assessment should proceed in parallel with efficacy assessment: first evaluating overall risk, then, whether exposure and safety risks are consistent across regions.

Key highlights include:

• Severity and frequency of safety issues
• Dose- or exposure-related risk
• Reversibility and tolerability
• Regionally significant adverse reactions
• Drug-drug interaction risks
• Risks relative to current therapy
• Region-specific influences (genetics, disease patterns, medical practice, drug accessibility)

 Pooled safety summaries alone are not sufficient to establish local relevance. Ensure Risk Management Measures Are Locally Applicable

Risk-management measures (e.g. dose adjustment, monitoring plans, prescribing guidance) should be globally consistent but also demonstrably applicable in the China clinical setting.

Identify and Evaluate Sources of Uncertainty

The guideline highlights uncertainty as a key consideration. MRCTs can introduce additional sources of uncertainty, including:

• Differences in disease characteristics and intrinsic/extrinsic factors
• Variability in trial execution
• Differences in exposure and follow-up
• Limited endpoint events
• Missing data and bias
• Sponsors are expected to document these uncertainties and assess their impact on benefit-risk conclusions.

Smaller Regional Datasets May Limit Safety Interpretation

Limited regional sample size or shorter observation periods may be insufficient to fully characterize region-specific safety risks, particularly for novel products.

Conduct Structured Analysis of Regional Inconsistencies

When regional results differ from global outcomes, sponsors should perform structured analysis rather than rely on numerical comparisons alone.

This includes evaluating:

• Sensitivity to the statistical methods
• Trial conduct differences Distribution of known intrinsic and extrinsic factors
• Potential biologically plausible unknown factors
• The role of random variation

Engage Early with the CDE on MRCT Strategy

The guideline emphasizes early sponsor-agency alignment. Sponsors planning to use MRCT data for China registration should engage early with the CDE on development strategy and key design elements, including endpoints, consistency assessment, and regional sample size.

Implications for Sponsors Pursuing China Registration

The guideline does not change China’s overall support for global development, but clarifies expectations:

• Relevance to Chinese patients should addressed early
• Statistical planning should support regional interpretation
• Benefit-risk must be justified at both global and China levels
• Residual uncertainty should be explicitly evaluated What This Means for International Sponsors

 The guideline provides a clearer framework for using MRCT data in China, reinforcing support for global development while requiring stronger regional justification and early planning.

For further guidance on China drug registration strategy and MRCT planning, companies may consult Cisema.

Further Information

Explore Cisema’s pharmaceutical development and regulatory services:

• Pharmaceutical Development & Strategy Consulting
• Pharmaceutical Regulatory Affairs Consulting

References

"Guiding Principles for Benefit-Risk Assessment Based on Multi-regional Clinical Trial Data in the Global Simultaneous R&D of New Drugs (Trial)" (No. 18 of 2026)